The United States is providing doses of an experimental Ebola drug for clinical testing in Africa, the Department of Health and Human Services (HHS) said on June 23.
Doses of the experimental antibody from California-based Mapp Biopharmaceutical are being transferred to the University of Oxford for a randomized clinical trial “in the outbreak region to evaluate its safety and potential efficacy against Bundibugyo ebolavirus,” a spokesperson for HHS told The Epoch Times via email.
The antibody, known as MPB134, targets multiple Ebola virus strains. It has shown efficacy in animal testing against the Bundibugyo virus, identified as being behind the growing Ebola outbreak centered in Congo….